Structural basis of respiratory syncytial virus neutralization by motavizumab.
Motavizumab is approximately tenfold more potent than its predecessor, palivizumab (Synagis), the FDA-approved monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection. The structure of motavizumab in complex with a 24-residue peptide corresponding to its epitope on the RSV fusion (F) glycoprotein reveals the structural basis for this greater potency. Modeling suggests that motavizumab recognizes a different quaternary configuration of the F glycoprotein than that observed in a homologous structure.
McLellan
Jason S
JS
Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Chen
Man
M
Kim
Albert
A
Yang
Yongping
Y
Graham
Barney S
BS
Kwong
Peter D
PD
D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000276:immunology; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing / Q000737:chemistry* / Q000276:immunology; D000914:Antibodies, Viral / Q000737:chemistry* / Q000276:immunology; D000998:Antiviral Agents / Q000737:chemistry* / Q000276:immunology; D018360:Crystallography, X-Ray; D000939:Epitopes / Q000737:chemistry* / Q000276:immunology; D006801:Humans; D008958:Models, Molecular; D009500:Neutralization Tests; D020836:Protein Structure, Quaternary; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D014760:Viral Fusion Proteins / Q000737:chemistry* / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D000998:Antiviral Agents; D000939:Epitopes; C526850:F protein, human respiratory syncytial virus; D014760:Viral Fusion Proteins; C506968:motavizumab